Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.
| 923.6 | |
| 923.6 | |
| - | |
| 937.6 | |
| 923.6 | |
| 671.3603-971.4211 | |
| 190 159 M | |
| 0 | |
| 26 303 M | |
| 5.6673 | |
| 0.0241 | |
| 0.328 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Coloplast A/S 9M 2023/24 Interim financial results, 9M 2023/24 1 October 2023 - 30 June 2024 Coloplast delivered 8% organic growth and an EBIT margin1) of 27% in Q3, with 11% growth in absolute EB...
As earnings season winds down, investors will still have plenty to watch next week as key companies across various sectors provide updates that could offer valuable insights into market trends. In th...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
